Application of carbon monoxide molecules in inhibition on acute rejection after skin grafting

Abstract

The invention discloses an application of carbon monoxide molecules in inhibition on acute rejection after skin grafting. According to a large number of cell tests, the inventor discovers that after the carbon monoxide molecules are dissolved into a dimethylsulfoxide (DMSO) solvent and placed into an organism, CO can be continuously released, so the carbon monoxide molecules can serve as exogenous CO donors. The skin of ICR mice and BALB / C mice can serve as a donor and a receptor; an allogeneic gene acute rejection model can be established; exogenous CO is injected into the caudal veins of the mice; and early intervention and the test are performed, so that the carbon monoxide release molecules have inhibition effect on the acute rejection after skin grafting. The carbon monoxide release molecules are used for inhibiting the acute rejection after skin grafting; the concentration is controlled relatively easily and correctly; during long-term use, the carbon monoxide release molecules are added conveniently; and the carbon monoxide molecules can serve as an immuno-inhibitor with high specificity, low toxicity and high efficiency.

Description

technical field [0001] The patent of the present invention relates to the new application of carbon monoxide releasing molecules in immunosuppression, and specifically relates to a method for early application of carbon monoxide releasing molecules to suppress acute rejection after skin transplantation. Background technique [0002] Allotranspantation is currently the main way to treat end-stage organ failure. As a convenient means of organ transplantation, allogeneic skin transplantation is not only widely used in the research of anti-graft rejection, but also solves the ethical problems caused by the lack of autologous skin and xenogeneic skin transplantation in clinical practice to a certain extent. However, in individuals who have received allogeneic tissue and organ transplantation, the MHC antigens of the grafts are recognized by the autoimmune system, resulting in rejection. As early as the 18th century, humans began to explore skin allografts. Initial attempts were...

AI Technical Summary

Problems solved by technology

However, due to the limitations of non-specific anti-immune rejection, many fatal complications will appear in the case of long-term administration of traditional immunosuppressants, such as tumors, low systemic immunity, central nervous system, liver and kidney function damage, etc.

Images